Background: This phase II study evaluated the clinical benefit of pegylated liposomal doxorubicin (PLD) and docetaxel (Taxotere) as first-line therapy for metastatic breast cancer (MBC). Results: Sixty-seven patients were included (group A, 53; group B, 14). In both groups, the median number of cycles delivered was 4 and the overall dose intensity was 82% for docetaxel and 71% for PLD. In group A, main toxic effects were hematologic, palmar-plantar erythrodysesthesia (PPE), and stomatitis. In group B, higher rates of grade 3-4 PPE, febrile neutropenia, and hematologic toxic effects were reported. The rate of clinical benefit was 47%. Among patients with a measurable disease, 49% achieved a partial response, 27% had a stable disease, and 13% progressed, according to RECIST criteria.
introduction
Although advances have been made in the management of breast cancer, the metastatic disease remains incurable, and long-term survivors are rare, with 5-year survival rates varying from 5% to 10% [1] . In the metastatic setting, strategies are based on improving survival while keeping the best quality of life. The targeted therapies, such as hormonal treatment of patients with hormone-sensitive tumors and trastuzumab in case of human epidermal growth factor receptor 2 overexpression, represent a treatment of choice for a subset of selected patients. Nevertheless, in patients who are not eligible for such treatments or in those who progress after targeted therapies, cytotoxic chemotherapy remains the only therapeutic option. In first-line treatment, meta-analyses have demonstrated that polychemotherapy provided higher response rates and significantly improved time to tumor progression (TTP) compared with monotherapy [2, 3] .
Anthracyclines and taxanes are the most active drugs for the treatment of metastatic breast cancer (MBC) [4, 5] . As first-line treatment of advanced breast cancer, randomized trials have demonstrated significant and consistent improvements in overall response rates (ORRs) for anthracycline-taxane combinations compared with anthracycline alone, as well as increased TTPs. However, the concomitant use of an anthracycline and a taxane results in higher toxicity, requiring dose reduction of both agents. Acute toxic effects of anthracyclines and taxanes are generally similar, consisting of myelosuppression, nausea-vomiting, stomatitis, and alopecia. A major concern with anthracyclines is cardiotoxicity, which represents a major issue in MBC patients who had previously received an anthracycline-based regimen in adjuvant setting.
Compared with doxorubicin, pegylated liposomal doxorubicin (PLD) has a prolonged circulation time and a different pattern of tissue distribution. The preferential uptake of pegylated liposomes by tumor tissue has been confirmed by gamma scintigraphy after the infusion of iridiummarked pegylated liposomes [6] . When used with doxorubicin, this approach was assumed to decrease circulating concentration of free doxorubicin and its toxic metabolite, doxorubicinol, to decrease the release of the active component in normal tissues, and to increase its concentration in tumoral tissues. Consequently, the toxicity profile of PLD is quite different from that of doxorubicin, with less cardiotoxicity and no alopecia but, in contrast, an increased risk of cutaneous toxic effects such as palmar-plantar erythrodysesthesia (PPE) [7] .
To improve the therapeutic index of an anthracycline-taxane combination, we evaluated the clinical benefit of PLD and docetaxel association in a phase II trial, CAPYTTOLE. The schedule was based on the results of a phase I study designed by the Groupe d'Investigateurs Nationaux pour l'Etude des Cancer de l'Ovaire et du sein, which demonstrated that the recommended doses of PLD and docetaxel were 35 mg/m 2 on day 1 and 40 mg/m 2 on days 1 and 15, respectively (cycles every 28 days) [8] . The primary end point was the rate of clinical benefit after six cycles of PLD-docetaxel. Secondary end points were safety, ORR, TTP, and survival.
patients and methods

study population
Patients aged at least 18 years with histologically or cytologically proven, measurable MBC were eligible. Prior adjuvant hormonotherapy, chemotherapy, and/or radiotherapy were allowed. If anthracyclines were used, treatment must have been completed at least 12 months before the study entry. A previous chemotherapy for MBC was not allowed. The other eligibility criteria included a World Health Organization (WHO) performance status of two or less and adequate hematologic, renal, cardiac, and hepatic functions. Patients were not eligible if they had isolated local recurrence, documented history of previous cancer, other significant medical conditions or any uncontrolled infection. Pregnant or breastfeeding women were excluded.
Written informed consent was obtained before enrollment. The protocol was reviewed and approved by the Ethics Committee/Institutional Review Board and the study was conducted according to the Declaration of Helsinki and European Good Clinical Practice requirements. . On day 1, docetaxel was administered one hour after the end of PLD infusion. To prevent docetaxelrelated hypersensitivity or fluid retention, patients received premedication with corticosteroids. For the prevention of PLD-related PPE, prophylactic pyridoxine (250 mg/day) was given systemically throughout the PLD treatment. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSF) and antibiotics was prohibited. Antiemetics (5-HT 3 receptor antagonists) were prescribed routinely before each cycle. Treatment was interrupted for at least 1 week in the event of an absolute granulocyte count <1.5 · 10 9 /l and/or a platelet count <100 · 10 9 /l on day 21. G-CSF (filgrastim 5 lg/kg/day on days 4-11) was prescribed for all subsequent chemotherapy cycles. In the event of febrile neutropenia, G-CSF was added after the first episode. The PLD dose adjustment according to the severity of PPE is described in Table 1 . Discontinuation of treatment was required for disease progression, unacceptable toxicity, WHO grade 3-4 cardiac event or fluid retention associated with weight gain. Treatment could also be discontinued at the discretion of the patient or investigator.
Because of unacceptable toxic effects, the protocol was amended modifying the chemotherapy regimen according to the schedule described by Alexopoulos et al. [9] , i.e. PLD 30 mg/m 2 on day 1 and docetaxel 75 mg/m 2 on day 2, every 3 weeks.
safety and efficacy assessments
Potentially eligible patients underwent a pretreatment evaluation including medical history, physical examination, serum biochemistry, absolute blood count, chest X-ray [and/or chest computed tomography (CT) scan], abdominal ultrasonography (and/or abdominal CT scan or magnetic resonance imaging), bone scan, and a left ventricular ejection fraction (LVEF) assessment by echocardiographic or radioisotopic method.
The hematologic toxicity was evaluated by blood tests carried out before each cycle. The non-hematologic toxicity was evaluated during the period between cycles, according to National Cancer Institute-Common Toxicity Criteria version 2.0. The LVEF was measured every three cycles and at the end of treatment.
The efficacy was assessed every two cycles. Target lesions were measured by homogeneous methods. For bidirectionally measurable lesions, the response was assessed according to RECIST.
statistical plan
This was a prospective, nonrandomized, phase II study. The primary end point was the rate of clinical benefit after six cycles of chemotherapy. The clinical benefit was defined as the rate of complete response, partial response (PR) plus disease stabilization lasting at least 6 months. The study original article
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was planned to test an estimated rate of clinical benefit of 65%, with a type I error (a) of 0.05 and a power of 80% (1-b) . This hypothesis required a sample size of 95 patients, taking into account a 10% rate of indeterminate patients. Secondary end points were safety, ORR, TTP, and survival. TTP was defined as the time from the onset of treatment until the first event (progression or death from any cause). Survival was defined as the time from the onset of treatment until death from any cause, or loss to followup. Survival data were computed according to the Kaplan-Meier method.
A safety interim analysis was planned after treatment completion of 30 patients. The safety rules were that the trial should be stopped if 50% of the nonprogressive patients experienced unacceptable toxic effects. Table 2 . Among the 38 patients who had received adjuvant chemotherapy, 36 (54%) had an anthracycline-based regimen. Fifty (75%) patients had an estrogen receptor-positive tumor, and progesterone receptors were positive in 34 patients (51%). Visceral metastases were present in 78% of the cases and were limited to one site in 73% of them.
From The planned safety analysis could not be carried out because the 30th patient included in May 2004 was still on treatment at the date of trial interruption. Treatment was prematurely discontinued in 30 patients because of toxicity in 22 (41.5%), disease progression in seven (13.2%), and one patient decided to stop treatment.
The level of treatment interruption due to toxicity led to stopping the initial schedule and to restarting with new proposed doses according to Alexopoulos et al. [9] . Fourteen additional patients were enrolled and treated accordingly (group B). Sixty-six cycles were administered, with a median number of four cycles (range 1-9). Treatment was discontinued before the sixth cycle because of toxicity in four patients, disease progression in three, and complication of a pathological fracture of femur in one. Only five patients received at least six cycles of chemotherapy, and one patient was not treated.
The overall dose intensity at cycle 6 was 82% for docetaxel and 71% for PLD. Changes in schedule and doses did not affect the rate of patients who prematurely stopped the treatment due to toxicity and therefore did not receive six cycles. The decision was made to stop the study after the enrollment of the 14 additional patients.
safety profile
The main grade 3-4 hematologic and non-hematologic toxic effects are described in Table 3 . Overall, no toxic deaths occurred.
In group A, non-hematologic toxicity was the main reason for postponing cycles of chemotherapy. The docetaxel dose was reduced because of PPE in 17% of patients, hematologic toxicity in 17%, and stomatitis in 12%. The PLD dose was reduced because of PPE in 25% of patients and in 10% for 
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stomatitis and/or hematologic toxicity. The actuarial curve showing the incidence of PPE per treatment group over time is presented in Figure 1 . In group B, the toxic profile was different, with higher rates of grade 3-4 PPE (43%), febrile neutropenia (14%), and hematologic toxic effects. On the other hand, stomatitis was less frequent.
efficacy results
The rate of clinical benefit was 47% in group A, 50% in group B, and 47% in the overall population. Given the similar results in both groups, the results were pooled. Among the 45 patients with measurable disease, 22 had a PR (ORR = 49%), 12 (27%) had a stable disease, six (13%) progressed, and five were not assessable.
Survival, duration of response, and TTP were not analyzed because of the premature interruption of the trial. Curves of TTP and overall survival are presented for indication ( Figure 2) . discussion This phase II trial was designed to evaluate the efficacy of a docetaxel-PLD combination in MBC patients. The primary end point was the clinical benefit, which differs from classical ORR used in MBC chemotherapy regimens, and was closer to the objective defined for hormonal treatment. This objective seemed more relevant, reflecting routine clinical practice. Toxic effects experienced by the first 52 patients resulted in a high rate (58%) of early discontinuation and an inadequate power to assess the primary end point. The modified schedule used for additional patients induced another pattern of toxic effects, mainly hematologic toxicity and PPE, leading to prematurely stopping the study.
Previously, three other phase I-II studies have evaluated the combination of PLD and docetaxel in MBC patients (Table 4 ) [9] [10] [11] . In 2001, Sparano et al. [10] published a phase I study with a dose escalation of PLD followed by fixed dose of docetaxel in 41 patients. With a G-CSF support, the maximal tolerated dose (MTD) was 30 mg/m 2 of PLD and 75 mg/m 2 of docetaxel every 4 weeks, whereas the MTD was 30 mg/m 2 of PLD and 60 mg/m 2 of docetaxel every 3 weeks in the absence of a G-CSF prophylaxis. In these patients, 67% received the four planned cycles. In 2004, Alexopoulos et al. [9] published a phase II study of PLD 30 mg/m 2 on day 1 and docetaxel 75 mg/m 2 on day 2 every 3 weeks in 44 patients with MBC. Patients received a median number of six cycles. Hematologic toxicity was the most frequent adverse event reported with 59% all-grade neutropenia and 9% febrile neutropenia. A PPE was reported in four patients (9%) and required a reduction in the PLD dose in two patients. No grade 3-4 stomatitis was reported. The treatment was discontinued in only one patient due to prolonged grade 3-4 neutropenia. In 2004, Morabito et al. [11] reported the results of a phase II study testing a combination of PLD and docetaxel in MBC patients. The PLD was administered at an initial dose of 30 mg/m 2 on day 1 and docetaxel at a fixed dose of 35 mg/m 2 on days 2 and 9, every 21 days. A PLD dose of 40 mg/m 2 was considered as the MTD after the first 15 patients, and the recommended dose of PLD was set at 35 mg/m 2 . The planned dose intensities of PLD and docetaxel were similar between these studies and ours, i.e. from 8.75 to 11.7 mg/m 2 /week of PLD and from 20 to 25 mg/m 2 /week of docetaxel [9] [10] [11] . The ORRs achieved were similar to those obtained when conventional doxorubicin 50 mg/m 2 was combined with docetaxel 75 mg/m 2 , ranging from 53% to 59% [12] [13] [14] . Regarding the toxicity profile, we found that hematologic toxicity and PPE were the main cumulative toxic effects of the PLD-docetaxel combination, which was in agreement with the findings of the other trials. Unexpectedly, the toxicity of the PLD-docetaxel combination was higher than the toxicity of the doxorubicin-docetaxel combination. A possible explanation could be pharmacokinetics interactions between PLD and docetaxel. Although pharmacokinetics interactions have been shown to be lower between PLD and docetaxel than between PLD and paclitaxel, the area under the curve (AUC) of PLD was increased in the presence of docetaxel (mean increase = 12%; P = 0.039) [15] . On the contrary, no change in AUC of doxorubicin was found when combined with docetaxel, whereas the AUC of docetaxel was increased by 50% original article Annals of Oncology to 70% [16] . The main interest in using PLD is to reduce the cardiotoxicity compared with the native doxorubicin. This has been previously demonstrated [7] and was confirmed in our study as well as in other trials evaluating the PLD-docetaxel combination in first-line therapy of MBC [9] [10] [11] .
Since MBC is a chronic and incurable disease, quality of life is an important issue to consider when choosing a therapeutic option. Toxic combinations should be avoided, unless they allow a better clinical outcome. Furthermore, a combined analysis of long-versus short-duration chemotherapy regimens showed that a longer treatment resulted in a longer TTP [17] . Thereby, cumulative toxicity is a major concern.
Our results highlighted a level of toxicity that is incompatible with the routine use of the docetaxel-PLD combination. Moreover, when combined with docetaxel, the efficacy results do not justify switching from doxorubicin to PLD. We believe the docetaxel-PLD association should not be considered firstline treatment of MBC. 
